Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Muscle-Invasive Bladder Carcinoma × Standard of Care × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 8 Neoplasm Metastasis 7 Carcinoma, Non-Small-Cell Lung 7 Neoplasms 6 Urinary Bladder Neoplasms 5 Colorectal Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 4 Prostatic Neoplasms 4 Lung Neoplasms 4 Leukemia, Myeloid, Acute 4 Triple Negative Breast Neoplasms 3 Ovarian Neoplasms 3 Mouth Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Ureteral Neoplasms 2 Recurrence 2 Oropharyngeal Neoplasms 2 Melanoma 2 Laryngeal Neoplasms 2 Head and Neck Neoplasms 2 Glioblastoma 2 Gastrointestinal Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma 2 COVID-19 2 Adenocarcinoma 2 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1 Tonsillar Neoplasms 1 Tongue Neoplasms 1

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04724928 2025-01-15

EFFORT-MIBC

University Hospital, Ghent

Phase 2 Recruiting

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡